30.1 C
New York
Saturday, June 6, 2026

Tag: plans

newssourceFORcompanyinformationcontent1marketreleases

From Bystanders to Heart Savers: MedStar Health CPR Training Event Puts Power to Save Lives in Community’s Hands

SILVER SPRING, Md., June 6, 2026 /PRNewswire/ -- MedStar Health marked CPR & AED Awareness Week with its third annual training event held at...

Are AI Crypto Trading Bots Suitable for Crypto Beginners? BulkQuant Launches an Automated Crypto Trading App

BulkQuant introduces an automated crypto trading app designed to help beginners access AI crypto trading bots with a simpler workflow, reduced manual operation, and clearer automation features. 
BulkQuant introduces an automated crypto trading app designed to help beginners access AI crypto trading bots with a simpler workflow, reduced manual operation, and clearer automation features.

All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance (Nasdaq: AIFA) (“AIFA” or the “Company”) today provided a strategic update. Following the Company’s previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group (“HyalRoute”) and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an “AI infrastructure network powered by optical technologies” and an “AI application services matrix.”

Former Pentagon Advisor: “The $2 Stock Sitting on America’s Greatest Untapped Treasure”

The opportunity has a June 30 deadline. One small company holds the key. And most Americans have no idea. 
The opportunity has a June 30 deadline. One small company holds the key. And most Americans have no idea.

Leading Vision Insurance for Glasses (2026): VSP Individual Vision Plans Named Top Plan for Frames and Lens Coverage by Better Business Advice

NEW YORK, June 6, 2026 /PRNewswire/ -- VSP® Individual Vision Plans has been recognized by Better Business Advice as a top vision insurance option...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Inturai Ventures Announces Adoption of Semi-Annual Reporting

(CSE: URAI  / OTC: URAIF / FSE: 3QG0)                                                                                                    investor@inturai.comVANCOUVER, BC, June 5, 2026 /CNW/ - Inturai Ventures Corp. (CSE: URAI) (OTC: URAIF) (FSE: 3QG0) (the...

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

DentaQuest Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information

Edelson Lechtzin LLP is investigating data privacy claims arising from the DentaQuest data breach.

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Yuno Provides Corporate Update as It Advances Toward Launch, Expands Leadership Team with Talent from Binance, and Positions for Global Prediction Market Growth

Yuno provided a corporate update ahead of launch, highlighting leadership growth, product progress, and global expansion plans.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPlans

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers